Cannabis-Based Sativex Boosts Profits At GW Pharma
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K. approval for Sativex breaks new regulatory ground, says company, clearing path for pipeline candidates.
You may also be interested in...
Pressure Is On Cannabinoid Drug Developer GW As Sativex Fails First Trial
GW Pharmaceuticals – a leader in development of cannabis plant-derived drugs – suffers setback with failure in its first Phase III study in cancer pain; results of two more studies are yet to be reported.
European HTA Highlights: Discounts Soften NICE Approach But Germany’s IQWiG Shows Its Teeth
It is becoming ever more clear that the overriding factor in NICE’s decision-making process is a desire to see cost-effectiveness, irrespective of the clinical benefit of a drug. But in Germany, companies are challenged by IQWiG’s tightened-up, science-based review system.
GW Pharmaceuticals PLC
GW is developing cannabis-based pharmaceuticals using extracts taken from plants which are specially bred to optimize the therapeutic benefit of cannabis.